Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Genome wide expression change by 786-O cells treated with MST1/2 inhibitor XMU-MP-1

ABSTRACT: Genome wide expression change by 786-O cells treated with MST1/2 inhibitor XMU-MP-1

PROVIDER: PRJNA810440 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR18143384.fastq.gz	Fastqsanger.gz
	SRR18143385.fastq.gz	Fastqsanger.gz
	SRR18143386.fastq.gz	Fastqsanger.gz
	SRR18143387.fastq.gz	Fastqsanger.gz
	SRR18143388.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 6

Similar Datasets

Genome wide expression change by 786-O cells treated with MST1/2 inhibitor XMU-MP-1

Project description:We aim to the investigate the role of MST1/2 inhibitor XMU-MP-1 in kindy renal clear cell carcinoma (ccRCC) progression. 786-O cells were used as the model.

2022-02-28 | GSE197468 | GEO

Genome wide expression change by C4-2 cells treated with MST1/2 inhibitor XMU-MP-1

Project description:We aim to the investigate the role of MST1/2 inhibitor XMU-MP-1 in prostate cancer progression. C4-2 cells were used as the model.

2021-10-26 | GSE186177 | GEO

Genome wide expression change by C4-2 cells treated with MST1/2 inhibitor XMU-MP-1

Project description:Genome wide expression change by C4-2 cells treated with MST1/2 inhibitor XMU-MP-1

| PRJNA772779 | ENA

XMU-MP-1, an inhibitor of the STE20-like MST1/2 kinases of the Hippo signaling pathway, induces hematopoietic tumor cells death

Project description:In this study we have shown that treatment of hematopoietic cells with XMU-MP-1, the inhibitor of MST1/2, the key components of the Hippo signaling pathway, causes inhibition of cell population growth and increased levels of caspase 3/7 activity. RNA-Seq analysis has demonstrated that XMU-MP-1 suppresses the expression of the key cell cycle regulators in the Namalwa cells: E2F family transcription factors, cell division cycle genes (CDC6; CDC7; CDC20; CDC25A,В,С, and CDC45), cyclins CCNА2, CCNB1, CCNB2; MCM2-7, ORC1 and ORC6. At the same time, XMU-MP-1 triggers the activation of the genes regulating apoptosis, necroptosis, and autophagy. XMU-MP-1 increases the expression of the apoptosis activator genes APAF1, caspases 6 and 7, FAS; BBC3, BCL2A1, MOAP1; XAF1. Some Namalwa cells may undergo necroptosis: XMU-MP-1 causes an increase in the expression of the necroptosis activator genes RIPK1, TNFSF10, TRADD, and PEA15, the inhibitor of caspase 8. The expression of the key genes activating autophagy is significantly increased (beclin 1; DEPP1; DAP; VPS18; VPS39, and autophagy regulator AMBRA1). The activation of these three processes in the B-cell tumor population indicates a profound effect of XMU-MP-1 on cell death in hematopoietic tumor cells. The treatment of Namalwa cells with XMU-MP-1 decreases their resistance to doxorubicin. The use of MST1/2 kinase inhibitors in the treatment of hematologic tumors may be extremely promising.

2025-07-02 | GSE279247 | GEO

Genome wide expression change by MCF-7 cells treated with MST1/2 inhibitor

Project description:Genome wide expression change by MCF-7 cells treated with MST1/2 inhibitor

| PRJNA693878 | ENA

Leukotriene B4 receptor 1 antagonist in combination with kinase MST1/2 inhibitor has potential for treatment of myocardial infarction

Project description:Timely inhibition of inflammation and initiation of resolution are important for the repair of injured tissues. Pharmacological inhibition of mammalian STE20-like protein kinase 1/2 (MST1/2) with XMU-MP-1 might augment tissue regeneration and repair by suppressing apoptosis and increasing cell proliferation. However, MST1 has anti-inflammatory activity, inhibition of which may result in therapy failure. Here, we identified an approach with the potential to overcome this limitation by protecting against cardiac inflammation resulting from inhibition of MST1 in macrophages. We found exacerbation of cardiac dysfunction in LysMCre-mediated Mst1/2-deficient mice after myocardial infarction (MI). This effect was attributed to a shift of macrophage subtypes from those expressing Cxcl2 and Cd163 toward those with Ccl2 and Ccl4 expression. Mass spectrometry identified leukotriene B4 (LTB4) as the lipid mediator that was upregulated in the absence of MST1. We found that MST1 phosphorylated 5-lipoxygenase (5-LOX) at its T218 residue, disrupting the interaction between 5-LOX and 5-LOX-activating protein, and resulting in reduction of LTB4 production. By contrast, a 5-LOXT218A variant showed no response to MST1. Moreover, treatment of peritoneal macrophages with LTB4 or with medium conditioned by Mst1-deficient macrophages resulted in high Ccl2 and Ccl4 expression and low Cxcl2 and Cd163 expression, except when the cells were co-treated with the LTB4 receptor 1 (BLT1) antagonist CP105696. Furthermore, CP105696 ameliorated cardiac dysfunction in LysMCre-mediated Mst1/2-deficient mice and enhanced cardiac repair in wild-type mice treated with XMU-MP-1 after MI. The combination of an MST1/2 inhibitor and a BLT1 antagonist represents a promising strategy for combatting the effects of MI.

2021-12-13 | GSE181935 | GEO

RNA sequencing data from wild type and Mst1/2 knockout esophageal epithelium

Project description:Hippo signaling regulates the homeostasis of multiple organs. Mst1 and Mst2 (Mst1/2) are critical components of the Hippo signaling pathway. Here, we utilized RNA sequencing to determine the transcriptional change in the esophageal epithelium upon Mst1/2 deletion. The analysis of gene expression profiles allows us to understand the role of Mst1/2 in the regulation of various biological processes in the esophageal epithelium.

2024-02-26 | GSE248501 | GEO

XMU-MP-1, an inhibitor of the STE20-like MST1/2 kinases of the Hippo signaling pathway, induces hematopoietic tumor cells death

Project description:XMU-MP-1, an inhibitor of the STE20-like MST1/2 kinases of the Hippo signaling pathway, induces hematopoietic tumor cells death

| PRJNA1171483 | ENA

786-O and 786-VHL in EMCV study

2010-06-10 | GSE22256 | GEO

786-O and 786-VHL in EMCV study

Project description:786-0 is a cell line derived from a clear cell renal carcinoma. Previous studies have shown that the 786-O cell line harbors an inactivating mutation in the von-Hippel Lindau (VHL) gene. Mutations in the VHL gene occur in the majority of sporadic clear cell renal cell. To determine how inactivation of the VHL affects cellular functions, we created a derivative of 786-0, which we call 786-VHL in which a functional allele of VHL has been introduced back into the 786-O cell line. The renal cell carcinoma cell line 786-0, which harbors a mutated allele of VHL, was compared to a cell line derived from 786-0, termed 786-VHL, that contains a functional allele of VHL. Genes whose expression characteristics were dependent on functional VHL were identified.

2010-06-23 | E-GEOD-22256 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data